Q&A: De­ter­mined to not re­peat mis­takes from the last pan­dem­ic, An­drey Zarur talks about lat­est deal with Serum In­sti­tute

The Mass­a­chu­setts biotech Green­Light made waves Mon­day with the an­nounce­ment of its li­cens­ing deal with the Serum In­sti­tute of In­dia. Three of its mR­NA prod­ucts, start­ing with its shin­gles vac­cine, will be pro­duced by Serum in a deal that pig­gy­backs off of its $10 mil­lion in­vest­ment from No­vem­ber.

Green­Light is rid­ing high off of its re­verse merg­er that net­ted it­self a $1.5 bil­lion val­u­a­tion, af­ter it merged with the SPAC En­vi­ron­men­tal Im­pact Ac­qui­si­tion Corp. It’s still work­ing on ex­per­i­men­tal vac­cines and ther­a­pies us­ing mR­NA tech­nol­o­gy for the sea­son­al flu and sick­le cell dis­ease, a long way from where it orig­i­nal­ly got its start: shak­ing up the pes­ti­cides mar­ket for agri­cul­ture.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER